Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06003465 · ClinicalTrials.gov registry record · Phase 1

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
57
Enrollment target
3
Study locations

NCT06003465 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 57 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06003465, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
57 participants
Enrollment target
3
Study locations

Study Summary

The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.

Conditions Studied

Interventions

  • DRUG LY3437943
  • DEVICE Test
  • DEVICE Reference

Study Locations (3)

Florida

  • Qps-Mra, Llc - Miami

Texas

  • ICON Early Phase Services - San Antonio

Utah

  • ICON - Salt Lake City

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2023-08-29
Est. Completion 2024-02-08
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT06003465

The ClinicalTrials.gov registry entry for NCT06003465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which LY3437943 is the first listed.

NCT06003465 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT06003465 about?

NCT06003465 is a clinical study titled "A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices". The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about an...

What is the current status of trial NCT06003465?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2023-08-29. Estimated completion is 2024-02-08.

What conditions does trial NCT06003465 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06003465?

The interventions under investigation include: LY3437943 (DRUG), Test (DEVICE), Reference (DEVICE).

Who is sponsoring clinical trial NCT06003465?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06003465 being conducted?

This trial has 3 study locations across Florida, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.